UK Spinraza Data Review Shows Benefits Of NICE Flexibility
Executive Summary
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
You may also be interested in...
Roche To Work On Reversing English Funding Rejection For SMA Drug
Evrysdi could follow Spinraza and Zolgensma to become the third treatment for spinal muscular atrophy available on England’s National Health Service if Roche can agree on a lower price for the drug.
Can The UK Remain A First Launch Market?
More pollical support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.
A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
NICE will review new data in deciding whether to OK the use of Spinraza in non-ambulant SMA type III patients.